Pharmaceuticals

TradingKey - On Monday, September 21, Eastern Time, futures on the three major US stock indices all rose in pre-market trading as high-level US-China talks sent positive signals. Meanwhile, Brent crude fell for the fourth consecutive trading session, temporarily easing market concerns over energy prices driving inflation.

TradingKey - On September 21, Novo Nordisk (NVO) shares fell more than 7% in US pre-market trading at one point. The company's latest financial results showed that while its full-year sales and profit guidance improved from previous forecasts, sales performance of its core weight-loss drug Wegovy still fell short of market expectations, becoming the primary factor weighing on the stock.

TradingKey - As Capital Markets Day approaches, Novo Nordisk (NVO) is facing mounting pressure from institutional investors.

TradingKey - On September 16, Novo Nordisk (NVO) announced a partnership with artificial intelligence company Anthropic to leverage Claude and related AI models to support drug discovery and development, while further advancing the application of AI in scientific research and software development.

TradingKey — On Tuesday (September 8) Eastern Time, futures tied to the three major U.S. stock indexes were mixed in pre-market trading. Iran announced that it would implement new restrictions in the Persian Gulf and the Gulf of Oman, while Yemen's Houthi movement attacked Saudi energy facilities, pushing international oil prices higher. Rising energy prices reignited inflation concerns, which, alongside the Japanese yen climbing to its highest level since February, weighed on market risk appetite.

TradingKey - In US pre-market trading on Tuesday, Novartis (NVS) shares fell approximately 13% after its experimental drug del-desiran for the treatment of myotonic dystrophy type 1 (DM1) failed to meet its primary endpoint in a Phase III clinical trial, marking the company's third clinical R&D setback within a week.